Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

Share Price is delayed by 15 minutes
Get Live Data
25.75    0.00 (0.00%)
Bid:
25.50
Ask:
26.00
Spread: 0.50 (1.961%)
Market Cap: £129.66m
DUKE Live PriceLast checked at - London Stock Exchange

Intraday Duke Capital Share Chart

Trading Update

1 Feb 2022 07:00

RNS Number : 2271A
Duke Royalty Limited
01 February 2022
 

1 February 2022

Duke Royalty Limited

("Duke Royalty", "Duke" or the "Company")

Trading Update

 

Duke Royalty, a provider of alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and North America, is pleased to provide the following trading update for its third financial quarter ended 31 December 2021 ("Q3 FY22"), and to provide guidance on trading for the last quarter of the Company's financial year ending 31 March 2022 ("Q4 FY22").

Financial Highlights:

· Q3 FY22 cash revenue, being monthly cash distributions from Duke's royalty partners plus cash gains received from the sales of equity assets and redemption premiums, totalled £3.9 million for the quarter which was in line with management's expectations and the trading update announced on 23 December 2021

· On a normalised cash revenue basis, which excludes the effects of redemption premium receipts and equity sales, normalised Q3 FY22 cash revenue also totalled £3.9 million which represented a record quarter for the Company, surpassing the £3.3 million generated in Q2 FY22. A table of the previous four quarters revenue is below.

· Based on current trading, Duke expects Q4 FY22 normalised cash revenue to be £4.4 million, which would again represent another record quarter of normalised cash revenue for the Company

 

Capital Deployments:

· Q3 FY22 saw record capital deployments by the Group in excess of £38 million which is more than double the amount deployed by Duke in any previous quarter

· Duke completed its largest new royalty financing to date with a US$21 million (approximately £15.9 million) investment into Atlas Signs Holdings, Inc., further expanding its presence in North America

· Also in December, Duke completed a £10.5 million royalty financing with Tristone Healthcare Limited ("Tristone"). As part of this financing, Duke has agreed to a total funding commitment of up to £20m to support Tristone's buy-and-build strategy

· Three follow-on investments into existing royalty partners were also completed during Q3 FY22 as follows:

· A £4.2 million investment into Bakchysarai (Ireland) Limited ("BIL") to finance their latest acquisition of Vantage Resources Limited

· A £5.3 million investment into Miriad Products, enabling the business to release equity value to certain principals and restructure its share register as part of which Duke increased its own shareholding to 30%

· A £5.3 million investment into Miriad Products, enabling the business to release equity value to certain principals and restructure its share register as part of which Duke increased its own shareholding to 30%

 

Duke Royalty's last four quarters of Normalised Cash Revenue and Total Cash Revenue are as follows:

 

Normalised Cash Revenue*

Total Cash Revenue

Q4 FY21

£2.5 million

£2.5 million

Q1 FY22

£2.9 million

£2.9 million

Q2 FY22

£3.3 million

£4.9 million

Q3 FY22

£3.9 million

£3.9 million

 

* Normalised cash revenue excludes redemption premium receipts and cash gains from equity sales

 

Neil Johnson, CEO of Duke Royalty, said:

"I am delighted to report that normalised cash revenue continued to grow to record levels in Q3 FY22. I expect this growth to continue into Q4 FY22 on the back of substantial new deployments made into both new and existing royalty partners.

"Duke's differentiated, long dated product offering is increasingly gaining traction in the marketplace. Our capital perfectly suits those companies wishing to minimise their refinancing risk and spend their time focussing on running, and expanding, their businesses."

 

***ENDS***

 

For further information, please visit www.dukeroyalty.com or contact:

 

 

Duke Royalty Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

 

+44 (0) 1481 730 613

Cenkos Securities plc 

(Nominated Adviser

and Joint Broker)

 

Stephen Keys / Callum Davidson / Julian Morse / Michael Johnson

 

+44 (0) 207 397 8900

 

 

 

 

Canaccord Genuity

(Joint Broker)

 

Adam James / Georgina McCooke

+44 (0) 207 523 8000

SEC Newgate (PR)

Elisabeth Cowell/ Richard Bicknell/ Megan Kovach

+44 (0) 20 3757 6882 dukeroyalty@secnewgate.co.uk

 

About Duke Royalty

 

Duke Royalty Limited provides alternative capital solutions to a diversified range of profitable and long-established businesses in Europe and abroad. Duke Royalty's experienced team provide financing solutions to private companies that are in need of capital but whose owners wish to maintain equity control of their business. Duke Royalty's royalty investments are intended to provide robust, stable, long term returns to its shareholders. Duke Royalty is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLALAILVIF
Date   Source Headline
28th May 20267:00 amRNSNotice of Results & Investor Presentation
31st Mar 20267:00 amRNSTrading and Operational Update
19th Mar 20267:00 amRNSInterim Dividend and Dividend Declaration
26th Jan 20267:00 amRNSDirector/PDMR Shareholding
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
22nd Dec 20257:00 amRNSFollow-On Investment into Tristone Healthcare Ltd
18th Dec 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Dec 20257:00 amRNSInterim Financial Results
17th Oct 20257:00 amRNSFollow-On Investment into Step Investments Limited
1st Oct 20257:00 amRNSFollow-On Investment into Integrum Group Holdings
29th Sep 20257:00 amRNSTrading Update
18th Sep 20257:00 amRNSInterim Dividend and Dividend Declaration
4th Aug 202511:17 amRNSResult of Annual General Meeting
1st Aug 20258:08 amRNSDirector/PDMR Dealings
11th Jul 20257:00 amRNSAnnual Report & Notice of Annual General Meeting
25th Jun 20257:00 amRNSFinal Results for the year ended 31 March 2025
19th Jun 20257:00 amRNSInterim Dividend and Dividend Declaration
2nd Jun 20257:00 amRNSFollow-On Investment into Existing Capital Partner
27th May 20257:00 amRNSNotice of Results & Investor Presentation
2nd Apr 20257:00 amRNSFollow-On Investment into Existing Capital Partner
31st Mar 20257:00 amRNSTrading and Operational Update
20th Mar 20257:00 amRNSInterim Dividend and Dividend Declaration
19th Feb 20257:00 amRNSFollow-On Investment into BPVA (Ireland) Limited
30th Dec 20247:00 amRNSTrading and Operational Update
17th Dec 202412:50 pmRNSInterim Dividend and Dividend Declaration
16th Dec 20247:00 amRNSInterim Results for the six months ended 30 Sep 24
4th Dec 20249:40 amRNSDirector/PDMR Shareholding
3rd Dec 202411:34 amRNSResult of General Meeting and Issue of Equity
22nd Nov 20243:38 pmRNSResult of Retail Offer and Broker Option
15th Nov 20247:00 amRNSResult of Placing
14th Nov 20245:02 pmRNSRetail Offer to raise up to £3.0 million
14th Nov 20245:01 pmRNSIssue of Equity
30th Sep 20247:00 amRNSTrading and Operational Update
19th Sep 20247:00 amRNSInterim Dividend and Dividend Declaration
3rd Sep 20247:00 amRNSFollow-On Investment into United Glass Group
1st Aug 20243:16 pmRNSDirector/PDMR Dealings
1st Aug 202411:40 amRNSResult of Annual General Meeting
22nd Jul 20247:00 amRNSFollow-On Investment into Step Investments Limited
15th Jul 20247:00 amRNSAnnual Report & Notice of Annual General Meeting
27th Jun 20247:00 amRNSFinal Results for the year ended 31 March 2024
20th Jun 202411:50 amRNSInterim Dividend and Dividend Declaration
3rd Jun 20247:00 amRNSNotice of Results
17th May 202411:45 amEQSHardman & Co Q&A on Duke Capital (DUKE) | Generating investor returns by uniquely meeting customer needs
3rd May 20247:00 amRNSFollow-On Investment into Existing Capital Partner
29th Apr 20242:45 pmEQSHardman & Co Research Initiation of Coverage on Duke Capital (DUKE): Meeting customer needs, giving investors returns
3rd Apr 20247:00 amRNSFollow-On Investment into Existing Capital Partner
2nd Apr 20247:00 amRNSNew Capital Partner - Integrum Care
28th Mar 20247:00 amRNSTrading and Operational Update
21st Mar 20247:00 amRNSInterim Dividend and Dividend Declaration
7th Mar 20247:00 amRNSSuccessful Exit of Investment in Fabrikat

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.